Benj Gallander Opko Health OPK-Q DON'T BUY Oct 08, 2014

The CEO has been buying an incredible amount of stock every single day. Insiders own about 51% of the company already. Maybe he knows something that we don’t know. This is not his kind of company at all. The debt load is over $200 million now. There is a lot of danger there. There is incredible revenue growth, but at the same time the company has been losing a lot of money.

Benj Gallander

Unlock Rating

$8.480

Stock price when the opinion was issued

Consumer Products

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

COMMENT

Their BioReference Labs division is currently testing all the NFL players as well as the NBA and MLS bubbles. Also testing federal US agencies and most recently New York schools. He's longed liked this company.

RISKY

Stuck in the mud. At best, this is a decent speculative stock.

BUY

It should be moving up and he's perplexed. Business is good. Their test for prostate cancer is the best there is. Puzzling.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Benj Gallander Opko Health OPK-Q DON'T BUY Oct 08, 2014

You might be interested:

Opko Health(OPK-Q)

Opko Health(OPK-Q)

Opko Health(OPK-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights